<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03658629</url>
  </required_header>
  <id_info>
    <org_study_id>qNIV-E-201</org_study_id>
    <nct_id>NCT03658629</nct_id>
  </id_info>
  <brief_title>Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults</brief_title>
  <official_title>Phase 2 Clinical Trial to Confirm the Dose and Formulation of a Recombinant Quadrivalent Nanoparticle Influenza Vaccine (Quad-NIV) With or Without Matrix-M1™ Adjuvant in Healthy Adults ≥ 65 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novavax</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novavax</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2 trial to confirm the dose and formulation, demonstrate adjuvant effect, and&#xD;
      evaluate the safety and tolerability of a single intramuscular injection of Quad-NIV with or&#xD;
      without Matrix-M1 adjuvant in healthy adults ≥ 65 years of age.&#xD;
&#xD;
      A total of approximately 1375 subjects will be randomized to seven treatment groups to&#xD;
      receive Quad-NIV or an active comparator.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized, observer-blind, active-controlled, Phase 2 trial will be conducted at&#xD;
      multiple sites. The composition of the Quad-NIV Influenza Vaccines to be used in this trial&#xD;
      includes recombinant H1, H3, and two B hemagglutinin proteins for the 2018-2019 Northern&#xD;
      Hemisphere influenza virus strains.&#xD;
&#xD;
      Approximately 1375 healthy male and female subjects ≥ 65 years will be randomized into 7&#xD;
      treatment groups, receiving various formulations of Quad-NIV, with or without Matrix-M1&#xD;
      adjuvant or one of two active comparator influenza vaccines. Within each site, randomization&#xD;
      will be stratified by history of receipt of 2017-2018 influenza vaccine. Subjects will&#xD;
      receive two injections 28 days apart. On Day 0, subjects will receive one of the five&#xD;
      Quad-NIV formulations or one of the two comparator influenza vaccines. On Day 28, subjects&#xD;
      will receive either placebo or a licensed influenza vaccine rescue dose, depending on his or&#xD;
      her initial randomization.&#xD;
&#xD;
      Subjects will be followed for safety for approximately 6 months, with primary immunogenicity&#xD;
      results at Day 28.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 24, 2018</start_date>
  <completion_date type="Actual">April 26, 2019</completion_date>
  <primary_completion_date type="Actual">November 27, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>Day 0 - Day 182</time_frame>
    <description>Solicited local and systemic adverse events over the 7 days post-injection; all adverse events (including adverse changes in clinical laboratory parameters) through 21 days post-injection; and MAEs, SAEs, and SNMCs through 6 months post-injection.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemagglutination Inhibition (HAI) Titers of vaccine homologous A and B influenza strains expressed as geometric man titer (GMT)</measure>
    <time_frame>Day 0 - Day 28</time_frame>
    <description>HAI antibody titers specific for the HA receptor binding domains of vaccine homologous A and B strain(s) at Days 0 and Day 28 post vaccination expressed as geometric man titer (GMT).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HAI titers of antigenically-drifted influenza strains expressed as GMT</measure>
    <time_frame>Day 0 - Day 28</time_frame>
    <description>HAI antibody titers specific for at least 2 antigenically-drifted influenza strains, at Days 0 and 28 post-vaccination expressed as geometric man titer (GMT).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HAI titers of vaccine-homologous A and B influenza strains expressed as GMT</measure>
    <time_frame>Day 0 - Day 182</time_frame>
    <description>HAI antibody titers specific for the HA receptor binding domains of vaccine-homologous A and B strain(s) expressed as GMT on Day 0,28,56 and 182.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAI titers of vaccine-homologous A and B influenza strains expressed as Geometric Mean Fold Ratio (GMFR)</measure>
    <time_frame>Day 28 - Day 182</time_frame>
    <description>HAI antibody titers specific for the HA receptor binding domains of vaccine-homologous A and B strain(s) expressed as GMFR on Day 28,56 and 182.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAI titers of vaccine-homologous A and B influenza strains expressed as Seroconversion Rate (SCR)</measure>
    <time_frame>Day 28 - Day 182</time_frame>
    <description>HAI antibody titers specific for the HA receptor binding domains of vaccine-homologous A and B strain(s) expressed as SCR on Day 28,56 and 182.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAI titers of vaccine-homologous A and B influenza strains expressed as Seroprotection Rate (SPR)</measure>
    <time_frame>Day 28 - Day 182</time_frame>
    <description>HAI antibody titers specific for the HA receptor binding domains of vaccine-homologous A and B strain(s) expressed as SPR on Day 28,56 and 182.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAI titers of antigenically-drifted influenza strains expressed as GMT</measure>
    <time_frame>Day 0 - Day 182</time_frame>
    <description>HAI antibody titers specific for antigenically-drifted influenza strains, at Days 0,28, 56 and 182 expressed as geometric man titer (GMT).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAI titers of antigenically-drifted influenza strains expressed as GMFR</measure>
    <time_frame>Day 28 - Day 182</time_frame>
    <description>HAI antibody titers specific for antigenically-drifted influenza strains, at Days 28, 56 and 182 expressed as GMFR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAI titers of antigenically-drifted influenza strains expressed as SCR</measure>
    <time_frame>Day 28 - Day 182</time_frame>
    <description>HAI antibody titers specific for antigenically-drifted influenza strains, at Days 28, 56 and 182 expressed as SCR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HAI titers of antigenically-drifted influenza strains expressed as SPR</measure>
    <time_frame>Day 28 - Day 182</time_frame>
    <description>HAI antibody titers specific for antigenically-drifted influenza strains, at Days 28, 56 and 182 expressed as SPR.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">1375</enrollment>
  <condition>Influenza, Human</condition>
  <arm_group>
    <arm_group_label>Quad-NIV Bedside Mix of Antigen and Adjuvant Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alternating deltoid injections of 2018-2019 Quad-NIV-1 (Day 0) and Placebo (Day 28)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quad-NIV Preformulated with Adjuvant Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alternating deltoid injections of 2018-2019 Quad-NIV-2 (Day 0) and Placebo (Day 28)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quad-NIV Preformulated with Adjuvant Dose B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alternating deltoid injections of 2018-2019 Quad-NIV-3 (Day 0) and Placebo (Day 28)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quad-NIV Preformulated with Increased B HA Adjuvant Dose A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alternating deltoid injections of 2018-2019 Quad-NIV-4 (Day 0) and Placebo (Day 28)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Quad-NIV without Adjuvant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alternating deltoid injections of 2018-2019 Quad-NIV-5 (Day 0) and Licensed 2018-2019 Influenza vaccine (Day 28)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Licensed High-Dose Trivalent Influenza Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alternating deltoid injections of 2018-2019 High-Dose Trivalent Vaccine (Day 0) and Placebo (Day 28)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Licensed Quadrivalent Influenza Vaccine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alternating deltoid injections of 2018-2019 Quadrivalent Vaccine (Day 0) and Placebo (Day 28)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>NanoFlu (Quad-NIV)</intervention_name>
    <description>2018-2019 Investigational Quadrivalent Seasonal Influenza Vaccine</description>
    <arm_group_label>Quad-NIV Bedside Mix of Antigen and Adjuvant Dose A</arm_group_label>
    <arm_group_label>Quad-NIV Preformulated with Adjuvant Dose A</arm_group_label>
    <arm_group_label>Quad-NIV Preformulated with Adjuvant Dose B</arm_group_label>
    <arm_group_label>Quad-NIV Preformulated with Increased B HA Adjuvant Dose A</arm_group_label>
    <arm_group_label>Quad-NIV without Adjuvant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Matrix-M Adjuvant</intervention_name>
    <description>Adjuvant</description>
    <arm_group_label>Quad-NIV Bedside Mix of Antigen and Adjuvant Dose A</arm_group_label>
    <arm_group_label>Quad-NIV Preformulated with Adjuvant Dose A</arm_group_label>
    <arm_group_label>Quad-NIV Preformulated with Adjuvant Dose B</arm_group_label>
    <arm_group_label>Quad-NIV Preformulated with Increased B HA Adjuvant Dose A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Licensed High-Dose Trivalent Influenza Vaccine</arm_group_label>
    <arm_group_label>Licensed Quadrivalent Influenza Vaccine</arm_group_label>
    <arm_group_label>Quad-NIV Bedside Mix of Antigen and Adjuvant Dose A</arm_group_label>
    <arm_group_label>Quad-NIV Preformulated with Adjuvant Dose A</arm_group_label>
    <arm_group_label>Quad-NIV Preformulated with Adjuvant Dose B</arm_group_label>
    <arm_group_label>Quad-NIV Preformulated with Increased B HA Adjuvant Dose A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluzone HD</intervention_name>
    <description>2018-2019 Licensed Trivalent Seasonal Influenza Vaccine</description>
    <arm_group_label>Licensed High-Dose Trivalent Influenza Vaccine</arm_group_label>
    <arm_group_label>Quad-NIV without Adjuvant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Flublok Quadrivalent</intervention_name>
    <description>2018-2019 Licensed Quadrivalent Seasonal Influenza Vaccine</description>
    <arm_group_label>Licensed Quadrivalent Influenza Vaccine</arm_group_label>
    <arm_group_label>Quad-NIV without Adjuvant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Clinically-stable adult male or female, ≥ 65 years of age. Subjects may have 1 or more&#xD;
             chronic medical diagnoses, but should be clinically stable as assessed by:&#xD;
&#xD;
               -  Absence of changes in medical therapy within 1 month due to treatment failure or&#xD;
                  toxicity,&#xD;
&#xD;
               -  Absence of medical events qualifying as serious adverse events within 2 months;&#xD;
                  and&#xD;
&#xD;
               -  Absence of known, current, and life-limiting diagnoses which render survival to&#xD;
                  completion of the protocol unlikely in the opinion of the investigator.&#xD;
&#xD;
          2. Willing and able to give informed consent prior to trial enrollment, and&#xD;
&#xD;
          3. Living in the community and able to attend trial visits, comply with trial&#xD;
             requirements, and provide timely, reliable, and complete reports of adverse events.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participation in research involving investigational product (drug / biologic / device)&#xD;
             within 45 days before planned date of first injection.&#xD;
&#xD;
          2. Participation in any previous Novavax's influenza vaccine clinical trial(s).&#xD;
&#xD;
          3. History of a serious reaction to prior influenza vaccination, known allergy to&#xD;
             constituents of licensed comparator vaccines or polysorbate 80.&#xD;
&#xD;
          4. History of Guillain-Barré Syndrome (GBS) within 6 weeks following a previous influenza&#xD;
             vaccine.&#xD;
&#xD;
          5. Received any vaccine in the 4 weeks preceding the trial vaccination and any influenza&#xD;
             vaccine within 6 months preceding the trial vaccination.&#xD;
&#xD;
          6. Any known or suspected immunosuppressive illness, congenital or acquired, based on&#xD;
             medical history and/or physical examination.&#xD;
&#xD;
          7. Chronic administration (defined as more than 14 continuous days) of immunosuppressants&#xD;
             or other immune-modifying drugs within 6 months prior to the administration of the&#xD;
             trial vaccine. An immunosuppressant dose of glucocorticoid will be defined as a&#xD;
             systemic dose ≥ 10 mg of prednisone per day or equivalent. The use of topical,&#xD;
             inhaled, and nasal glucocorticoids will be permitted.&#xD;
&#xD;
          8. Administration of immunoglobulins and/or any blood products within the 3 months&#xD;
             preceding the administration of the trial vaccine or during the trial.&#xD;
&#xD;
          9. Acute disease at the time of enrollment (defined as the presence of a moderate or&#xD;
             severe illness with or without fever, or an oral temperature ≥ 38.0°C, on the planned&#xD;
             day of vaccine administration).&#xD;
&#xD;
         10. Any condition that in the opinion of the investigator would pose a health risk to the&#xD;
             subject if enrolled or could interfere with evaluation of the vaccine or&#xD;
             interpretation of trial results (including neurologic or psychiatric conditions deemed&#xD;
             likely to impair the quality of safety reporting).&#xD;
&#xD;
         11. Known disturbance of coagulation.&#xD;
&#xD;
         12. Suspicion or recent history (within 1 year of planned vaccination) of alcohol or other&#xD;
             substance abuse.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vivek Shinde, MD</last_name>
    <role>Study Director</role>
    <affiliation>Novavax</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>US135</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US045</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US013</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US138</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20854</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US025</name>
      <address>
        <city>Norfolk</city>
        <state>Nebraska</state>
        <zip>68701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US018</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US078</name>
      <address>
        <city>Cary</city>
        <state>North Carolina</state>
        <zip>27518</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US108</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US137</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US132</name>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <zip>28625</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US071</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US063</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US056</name>
      <address>
        <city>Moncks Corner</city>
        <state>South Carolina</state>
        <zip>29461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>US050</name>
      <address>
        <city>Dakota Dunes</city>
        <state>South Dakota</state>
        <zip>57049</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://novavax.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 31, 2018</study_first_submitted>
  <study_first_submitted_qc>August 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2018</study_first_posted>
  <disposition_first_submitted>December 4, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>April 24, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">April 28, 2020</disposition_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

